About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
MDGL - Madrigal Pharmaceuti...| Previous Close | $110.00 | Open | |
| Volume | Market Cap | 1.674B | |
| Yield | Last Dividend |
| Better Buy: Intercept Pharmaceuticals vs... | 06/18/20 |
| These two companies are going after the same target, but which one should you bet on today? | |
| The Daily Biotech Pulse: Cumberland's Po... | 05/27/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC ... | |
| The Daily Biotech Pulse: FDA Nod For Roc... | 05/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC ... | |
| The Daily Biotech Pulse: Fate Therapeuti... | 04/03/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BEL... | |
| 10 US colleges and universities where fe... | 03/22/20 |
| To date, there have been some 6,940 female company founders whose businesses have received more than $1 million in funding, according to research by U... | |
| The future of these 7 biotechs hinges on... | 02/25/20 |
| There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplant... | |
| Why Madrigal Pharma Stock Could Still Do... | 01/30/20 |
| No summary available. | |
| The Daily Biotech Pulse: Acceleron's Pos... | 01/28/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) ... | |
| The Daily Biotech Pulse: FDA Nod For Epi... | 01/24/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Jan. 23) ... | |
| IBI Blogs On Holidays: Merry Christmas, ... | 12/25/19 |
| This morning, I sent you the Christmas gift, i.e. the research on Madrigal Pharmaceuticals (MDGL). In the spirit of the holiday, I'm giving you anothe... | |
| Madrigal Pharmaceuticals : Reports 2019 ... | 11/06/19 |
| Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., November 6, 2019 -- Madrigal??? | November 6, ... | |
| Hedge Funds Are Dumping Madrigal Pharmac... | 10/26/19 |
| We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook a... | |
| The Daily Biotech Pulse: Arbutus Halts H... | 10/04/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Ap... | |
| Madrigal, Galmed, And Galectin In Phase ... | 05/22/19 |
| No summary available. | |
| Noteworthy Friday Option Activity: MDGL,... | 05/17/19 |
| Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Madrigal Pharmaceuticals Inc Symb... | |
| Madrigal Pharmaceuticals beats by $0.06 | 05/08/19 |
| No summary available. | |
| IPO Update: Axcella Health Readies Plan ... | 05/02/19 |
| No summary available. | |
| MGL-3196: Not Ideal, But Currently The B... | 04/16/19 |
| No summary available. | |
| NASH players in the red as EASL announce... | 04/11/19 |
| No summary available. | |
| Viking ahead 7% premarket on new VK2809 ... | 04/11/19 |
| No summary available. | |
| 3 Stocks To Hold During The Economic Slo... | 03/30/19 |
| No summary available. | |
| Madrigal Pharma launches late-stage stud... | 03/28/19 |
| No summary available. | |
| Madrigal Pharmaceuticals Initiates Phase... | 03/28/19 |
| -- Investigator meeting held March 21/22, 2019 -- -- In Phase 2 study resmetirom was statistically significantly superior to placebo in resolving NASH... | |
| Viking Therapeutics up 7% premarket on p... | 03/27/19 |
| No summary available. | |
| Conatus flop fails to move NASH players | 03/22/19 |
| No summary available. | |
| IPO Update: Genfit Files Proposed Terms ... | 03/19/19 |
| No summary available. | |
| Conatus up 22% ahead of Emricasan data p... | 03/13/19 |
| No summary available. | |
| Madrigal Pharmaceuticals beats by $0.02 | 02/27/19 |
| No summary available. | |
| Intercept data stokes NASH players | 02/19/19 |
| No summary available. | |
| Buy rating | 06/05/20 |
| BMO Capital initiates coverage with Market Perform rating and announces Price Target of $135.00 | |
| Buy rating | 05/22/20 |
| B. Riley FBR maintains Buy rating and raises Price Target from $134.00 to $174.00 | |
| Buy rating | 05/08/20 |
| H.C. Wainwright maintains Buy rating and lowers Price Target from $215.00 to $168.00 | |
| Buy rating | 05/05/20 |
| Chardan Capital initiates coverage with Buy rating and announces Price Target of $205.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Free Biotech Holdings | Scientia Equity Research | 100.00 % | Follow |
| AungPan Thar's Swing trading | Kyaw Aung | 65.00 % | Subscribe |
| Biotech Fund | Scientia Equity Research | 58.00 % | Subscribe |
| Long Only Biotech/Pharma | Biotech Buys | 33.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
